Clinical Trials Logo

Vascular Diseases clinical trials

View clinical trials related to Vascular Diseases.

Filter by:

NCT ID: NCT03669042 Completed - Clinical trials for Peripheral Arterial Disease

Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vascular Surgery

PHOTO-V
Start date: November 20, 2018
Phase: N/A
Study type: Interventional

The objective of this post-market clinical follow-up study is to evaluate the clinical outcomes of patients receiving PhotoFix as a patch within a vascular repair or reconstruction procedure.

NCT ID: NCT03604939 Completed - Breast Cancer Clinical Trials

Improving Access to Control of Diseases for Women

IMPACD
Start date: January 1, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the feasibility and acceptability of the model of delivering CHW-driven home-based comprehensive NCD control services aimed to prevent premature deaths from cardio-vascular diseases, stroke and breast, cervix and oral cancers in the hard-to-reach women.

NCT ID: NCT03518203 Completed - Clinical trials for Atypical Hemolytic Uremic Syndrome

Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

Start date: August 3, 2018
Phase: Phase 2
Study type: Interventional

Hematopoietic stem cell transplantation (HCT)-associated thrombotic microangiopathy (TMA) is an understudied complication of HCT that significantly affects transplant related morbidity and mortality. The investigators hypothesize that early intervention with complement blocker eculizumab will double survival in HCT recipients with high risk TMA, as compared to historical untreated controls. An optimal eculizumab dosing schedule can be determined for this population through eculizumab pharmacokinetic/pharmacodynamic (PK/PD) testing.

NCT ID: NCT03511157 Completed - Clinical trials for Peripheral Arterial Disease

Ischemic Preconditioning Claudication Study

Start date: June 14, 2018
Phase: N/A
Study type: Interventional

This study proposes ischemic preconditioning (IPC) as a novel intervention to improve walking distance in patients with intermittent claudication.

NCT ID: NCT03496948 Completed - Clinical trials for Cardiovascular Diseases

Telephone Health Coaching and Remote Exercise Monitoring for Peripheral Artery Disease

TeGeCoach
Start date: April 23, 2018
Phase: N/A
Study type: Interventional

Peripheral artery disease (PAD) is the third most prevalent cardiovascular disease worldwide, with over 200 million people affected. Most prominent symptom is leg pain while walking known as intermittent claudication. Based on the currently existing gaps in the management of intermittent claudication, the objective of the this study is to explore the clinical effectiveness and cost advantage of TeGeCoach, a 12-month long home-based exercise program, compared to usual care. TeGeCoach consists of telephone health coaching, remote walking exercise monitoring based on wearable activity monitors and intensified primary care. It is hypothesized that TeGeCoach will improve functional outcomes and will reduce total health care costs.

NCT ID: NCT03477227 Completed - Vascular Diseases Clinical Trials

New Compression Hosiery Versus Standard Class II Compression Stockings After Endothermal Ablation

COSMOS
Start date: December 29, 2017
Phase: N/A
Study type: Interventional

A prospective comparative randomized multicentre non-inferiority trial. The purpose of this study is to compares of a short compression hosiery (stocking without a foot, compression class 2) with standard compression class 2 stockings for 7 days after the endovascular radiofrequency ablation of great saphenous vein with phlebectomy varicose tributaries.

NCT ID: NCT03466255 Completed - Clinical trials for Myocardial Infarction

Early Detection of Cardiovascular Disease

VIBE
Start date: December 6, 2016
Phase:
Study type: Observational

The investigators plan to evaluate the correlation between carotid plaque enhancement on Contrast-enhanced ultrasound (CEUS), significant coronary artery disease (CAD), and cardiovascular (CV) outcomes in a systematic manner. The investigators hypothesize that increased levels of CEUS-detected vulnerable carotid plaque will be predictive of CV risk determined by angiography and future cardiovascular events.

NCT ID: NCT03460587 Completed - Stroke Clinical Trials

Long-term Telerehabilitation for Patients With Stroke

Start date: August 29, 2018
Phase: N/A
Study type: Interventional

The aim of the current protocol is to study 40 patients, each for 12 weeks, to address hypotheses related to the ability of a telerehabilitation system to (a) improve motor status and disability, (b) collect various forms of patient data from the home, (c) improve risk factor knowledge and control, and (d) assess patient compliance with home-based telerehabilitation. Patients who have returned to their home after stroke will be provided with a telehealth system and be asked to use it 6 days/week for 12 weeks, during which time subjects will use this system for daily rehabilitation therapy, assessments, and education--all on one platform.

NCT ID: NCT03459144 Completed - Clinical trials for Polypoidal Choroidal Vasculopathy

Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen

Start date: December 1, 2012
Phase: N/A
Study type: Interventional

The aim of this study is to compare the outcomes of different treatment methods including photodynamic therapy (PDT), intravitreal ranibizumab injection (IVR) and combination therapy under the "1+PRN" treatment regimen for polypoidal choroidal vasculopathy (PCV) and find the optimal treatment for PCV.

NCT ID: NCT03448159 Completed - Stroke Clinical Trials

Fluoxetine Opens Window to Improve Motor Recovery After Stroke

FLOW
Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

The FLOW trial is a randomized placebo-controlled trial analyzing the effect of coupling an anti-depressant, fluoxetine (Prozac), and exercise to improve motor recovery following a stroke.